Vanguard Group Inc Cardiff Oncology, Inc. Transaction History

Vanguard Group Inc

  • $5.57 Trillion
  • Q4 2024

A detailed history of Vanguard Group Inc transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 2,284,917 shares of CRDF stock, worth $9.69 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,284,917
Previous 2,171,444 5.23%
Holding current value
$9.69 Million
Previous $5.8 Million 71.05%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 11, 2025
BUY
$2.31 - $5.35 $262,122 - $607,080
113,473 Added 5.23%
2,284,917 $9.92 Million
Q3 2024

Nov 13, 2024
BUY
$2.05 - $2.77 $71,967 - $97,243
35,106 Added 1.64%
2,171,444 $5.8 Million
Q2 2024

Aug 13, 2024
BUY
$2.22 - $5.89 $477,479 - $1.27 Million
215,081 Added 11.19%
2,136,338 $4.74 Million
Q1 2024

May 10, 2024
BUY
$1.46 - $5.91 $13,823 - $55,955
9,468 Added 0.5%
1,921,257 $10.3 Million
Q4 2023

Feb 14, 2024
SELL
$0.96 - $1.55 $29,883 - $48,249
-31,129 Reduced 1.6%
1,911,789 $2.83 Million
Q4 2022

Feb 10, 2023
BUY
$1.22 - $1.66 $1,061 - $1,444
870 Added 0.04%
1,942,918 $2.72 Million
Q3 2022

Nov 14, 2022
BUY
$1.54 - $3.21 $287,043 - $598,318
186,392 Added 10.62%
1,942,048 $2.99 Million
Q2 2022

Aug 12, 2022
SELL
$1.17 - $2.61 $184,575 - $411,745
-157,757 Reduced 8.24%
1,755,656 $3.86 Million
Q1 2022

May 13, 2022
SELL
$2.11 - $7.25 $96,051 - $330,034
-45,522 Reduced 2.32%
1,913,413 $4.75 Million
Q4 2021

Feb 14, 2022
BUY
$5.18 - $7.24 $756,212 - $1.06 Million
145,987 Added 8.05%
1,958,935 $11.8 Million
Q3 2021

Nov 12, 2021
BUY
$5.01 - $7.58 $836,189 - $1.27 Million
166,904 Added 10.14%
1,812,948 $12.1 Million
Q2 2021

Aug 13, 2021
BUY
$6.65 - $10.04 $10.9 Million - $16.5 Million
1,646,044 New
1,646,044 $10.9 Million

Others Institutions Holding CRDF

# of Institutions
125
Shares Held
25.3M
Call Options Held
866K
Put Options Held
203K
View Full List

About Cardiff Oncology, Inc.

CRDF Quotes by TradingView
  • Ticker CRDF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,334,900
  • Market Cap $184M
  • Description
  • Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...
More about CRDF
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email